Article: Getting The Most From Preclinical Imaging

By Patrick McConville, Ph.D.

The pharmaceutical industry continues to actively adopt imaging technologies to accelerate the drug discovery process. Imaging methods such as magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), computed tomography (CT), and in vivo optical imaging offer important and valuable improvements over traditional drug discovery methods.

These improvements include providing earlier and more highly predictive in vivo data, facilitating clinical translation, and yielding highly quantitative information from the more realistic models of disease that are becoming increasingly available.

Used with permission from Life Science Leader magazine.

Read more...